167 related articles for article (PubMed ID: 32020720)
41. Proinflammatory cytokines as serum biomarker in oral carcinoma-A prospective multi-biomarker approach.
Schiegnitz E; Kämmerer PW; Schön H; Blatt S; Berres M; Sagheb K; Al-Nawas B
J Oral Pathol Med; 2018 Mar; 47(3):268-274. PubMed ID: 29272054
[TBL] [Abstract][Full Text] [Related]
42. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
43. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis.
Abbas A; Gregersen I; Holm S; Daissormont I; Bjerkeli V; Krohg-Sørensen K; Skagen KR; Dahl TB; Russell D; Almås T; Bundgaard D; Alteheld LH; Rashidi A; Dahl CP; Michelsen AE; Biessen EA; Aukrust P; Halvorsen B; Skjelland M
Stroke; 2015 Mar; 46(3):793-9. PubMed ID: 25649806
[TBL] [Abstract][Full Text] [Related]
44. Serum IL-23, E-selectin and sICAM levels in non-small cell lung cancer patients before and after radiotherapy.
Kiziltunc Ozmen H; Simsek M
J Int Med Res; 2020 May; 48(5):300060520923493. PubMed ID: 32419551
[TBL] [Abstract][Full Text] [Related]
45. Overexpressed C14orf166 associates with disease progression and poor prognosis in non-small-cell lung cancer.
Zhou YW; Li R; Duan CJ; Gao Y; Cheng YD; Zhang CF
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30126850
[TBL] [Abstract][Full Text] [Related]
46. Suppression of human and mouse Th17 differentiation and autoimmunity by an endogenous Interleukin 23 receptor cytokine-binding homology region.
Guo W; Luo C; Wang C; Wang YH; Wang X; Gao XD; Yao WB
Int J Biochem Cell Biol; 2014 Oct; 55():304-10. PubMed ID: 25263529
[TBL] [Abstract][Full Text] [Related]
47. Expression of IL-23R and IL-17 and the pathology and prognosis of urinary bladder carcinoma.
Liu J; Wang L; Wang T; Wang J
Oncol Lett; 2018 Oct; 16(4):4325-4330. PubMed ID: 30214568
[TBL] [Abstract][Full Text] [Related]
48. High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer.
Wei F; Yang F; Jiang X; Yu W; Ren X
Tumour Biol; 2015 Dec; 36(12):9405-10. PubMed ID: 26113410
[TBL] [Abstract][Full Text] [Related]
49. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
[TBL] [Abstract][Full Text] [Related]
50. Up-regulation of long noncoding RNA uc.338 predicts poor survival in non-small cell lung cancer.
Tian Y; Feng Y
Cancer Biomark; 2018; 22(4):781-785. PubMed ID: 29843223
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of serum miR-25 in non-small-cell lung cancer.
Li J; Yu M; Liu Z; Liu B
Br J Biomed Sci; 2019 Jul; 76(3):111-116. PubMed ID: 30919763
[No Abstract] [Full Text] [Related]
52. Elevated serum levels of soluble interleukin-2 receptors in small cell lung carcinoma.
Yamaguchi K; Nishimura Y; Kiyokawa T; Matsuzaki H; Ishii T; Kubota K; Kawahara M; Furuse K; Yoshinaga T; Kinuwaki E
J Lab Clin Med; 1990 Oct; 116(4):457-61. PubMed ID: 2170552
[TBL] [Abstract][Full Text] [Related]
53. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
Mo D; He F
Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
[TBL] [Abstract][Full Text] [Related]
54. Serum microRNA-135a downregulation as a prognostic marker of non-small cell lung cancer.
Zhang YK; Sun B; Sui G
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27525941
[TBL] [Abstract][Full Text] [Related]
55. The close association between IL‑12Rβ2 and p38MAPK, and higher expression in the early stages of NSCLC, indicates a good prognosis for survival.
Liu Z; Yang W; Yang S; Cai K
Mol Med Rep; 2018 Aug; 18(2):2307-2313. PubMed ID: 29956791
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.
Xu CH; Wang W; Lin Y; Qian LH; Zhang XW; Wang QB; Yu LK
Oncotarget; 2017 Mar; 8(12):18746-18753. PubMed ID: 27816968
[TBL] [Abstract][Full Text] [Related]
57. [The clinical significance of β-arrestin 2 expression in the serum of non-small cell lung cancer patients].
Wu Z; Tong W; Tan Z; Wang S; Lin P
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):497-501. PubMed ID: 21645452
[TBL] [Abstract][Full Text] [Related]
58. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis.
Orditura M; De Vita F; Catalano G; Infusino S; Lieto E; Martinelli E; Morgillo F; Castellano P; Pignatelli C; Galizia G
J Interferon Cytokine Res; 2002 Nov; 22(11):1129-35. PubMed ID: 12513912
[TBL] [Abstract][Full Text] [Related]
59. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
[TBL] [Abstract][Full Text] [Related]
60. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
